Tuesday, March 17, 2009

Stocks on the Move: SIRI, BDSI, CPST

SIRI, Sirius Satellite Radio:

In short time SIRI has gone from a stock to watch, to a stock bound for recovery to a stock on the move.

Just a month ago the SIRI stock was trading for six cents as news of a possible bankruptcy loomed, but Liberty Media stepped in and pulled SIRI from the brink of shareholder devastation.

Since then, the stock has pushed upwards to where it is trading today- over thirty cents. Not a bad return for investors that were buying at/around/below ten cents.

The rise in stock price has as much to do with short covering, in my opinion, as it does with good news originating from the company.

As shorts began to cover, good news came in the form on an announcment that Sirius XM will soon be compatible with the iPhone. The iPhone application, combined with the recent price hikes, should enable the company to offset a decline in new subscriptions.

While the declining new subscription growth is worrisome, the fact that the company was able to net positive subscription growth in one of the worse quarters in recent history (both financially and for consumer spending) speaks volumes for the potential of the company, and it's stock.

A recent string of bad press by some 'Fools' out there has done little to halt the upward progression of the stock, and it's likely that the authors of the bad press are trying to keep the stock as low as possible to allow their 'short' friends to cover.

Nonetheless, SIRI is still a good long term pick, in my opinion, and while I'm already set in my position, I may add on any significant dips.

Sirius Satellite Radio Inc.

BDSI, BioDelivery Sciences International:

VFC's 2009 Stock Picks Part I

BDSI has recently pushed to the mid three dollar level, a buck above where it was trading only a month ago.

BioDelivery Sciences is awaiting FDA approval for it's lead drug candidate, Onsalis, by mid year.

All indications up to this point are that Onsolis, a treatment for pain in opioid tolerant patients with cancer, has a good chance of approval.

With the market on somewhat of a rally, investors will be more willing to risk some capital in the risky biotech sector and companies with FDA decisions pending should benefit.

Regarding Onsolis, the company also recently announced that it has expanded a pre-existing partnership with Meda AB that provided BioDelivery Sciences with a $3 million advance from the $30 million milestone payment the Meda will pay upon Onsolis approval. In return, Meda AB now has exclusive rights to distribute Onsolis in all countries except Taiwan and South Korea.

The current volatility and upward price movement of BDSI comes strictly from the pending FDA decision on Onsolis, but BioDelivery Sciences also has two additional drug candidates in early stages of development. However, these drugs are pretty far off and should not be a consideration when choosing to invest in BDSI.

FDA plays are always risky, but BDSI is currently on the move.

Bliss World, LLC

CPST, Capstone Turbine:

Capstone Turbine, the maker of energy efficient and 'green' microturbines, recently announced that they have sold their First C200 in Shanghai, which will be installed into the "Shanghai Shenergy Energy Center" highrise.

The CPST stock has been beaten down along with the market to a recent low of thirty nine cents, but it looks to have bounced from that level and possibly turned the corner towards the one dollar level.

With a large backlog of orders for the company's microturbines, Capstone is well positioned to take advantage of the global shift towards 'clean energy.'

On the downside, the company has yet to turn a profit, but the company has recently undertaken some cost-cutting measures to improve the bottom line and has an open line of credit- an essential in this market.

CPST was a stock trading for above four dollars not so long ago and the possibility of it returning to that level anytime soon is slim.

However, Capstone may be the right company at the right time and it's stock is heavily discounted while it is trading below one dollar, in my opinion.

A recent run has the stock trading in the high sixty cent range, a 60% increase from it's recent lows.

I'm still buying on the dips, but the risk of buying below a buck is worth the possible reward in this energy-efficient envrionment.


Sunday, March 15, 2009

Stock Watch: DNDN, NVD, BBI

DNDN, Dendreon:

Dendreon's May Release Early Provenge Results

Shares of Dendreon (DNDN) soared last week as the entire market rallied, but there is more to the Dendreon story that should have investors tuning in for at least the next few months.

Earlier this year, Dendreon's CEO reported that final results of the ongoing Provenge Phase III trial, known as IMPACT, may be released as early as April. Long time investors of DNDN know that the trading days approaching the release of big news regarding Provenge brings a large amount of volatility to the stock- giving traders a chance to trade in and out and long term investors the chance to add to their positions on the dips.

In the past week DNDN spiked to over four dollars after having traded in the mid twos as the market dropped.

The mid term results for the IMPACT trial, released by Dendreon last October, indicated that Provenge worked, but the trial did not meet the main endpoint of 22%- meaning patients receiving Provenge were not 22% less likely to die, only 20% less likely. It doesn't sound like much, but in the world of medicine and clinical trials, that's a world apart.

As D-Day for trial results approaches, DNDN should increase in both price and volume as investors hedge their bets on both sides of the Provenge Story. Positive results could push DNDN 200% to the upside while a huge miss from the 22% goal could make DNDN a dollar stock.

However, there could be a middle road. That scenario would be results in between the midterm mark of 20% and the target mark of 22%. In that case Dendreon would probably push for FDA approval and hope the new administration at the FDA takes a different stance than the previous one that overuled their own FDA advisory panel that voted Provenge safe 17-0 and effective by a 13-4 margin. Ignoring the advisory panel votes, the FDA issued an 'approvable' letter for Provenge, pending the results of the IMPACT trial.

Provenge has a long and storied history, including accusations of conflicts of interests by two doctors who served on the advisory panel and then lobbied against the approval of Provenge, and the stock has seen it all with a spikes up to the mid twenties and drops into the mid twos. From here on out things should get interesting.

Dendreon traded at over four times normal volume on Friday alone and DNDN should be one of the more exciting stocks to watch for the next two months.

In addition, the large contingency of prostate cancer patients who have lobbied hard to get Provenge approved will be hoping to finally be able to have another option other than the chemo that is now their only hope.

VFC is set with out-of-the-money May calls and a nice chunk of DNDN stock.

'Cancer vaccines, Where are they now?'- From Sept '08

ShareBuilder - Welcome page

NVD, Novadel Pharma Inc:

Another big mover on Friday was NVD. Novadel has been hammered of late, trading as low as five cents in this bear market, but the company has two approved drugs (Zolpimist and Nitromist), a solid pipeling and is a fine candidate for either a partnership or a buyout. All of Novadel's drug candidates use NovaDel's proprietary NovaMist oral spray technology.

After hovering at twenty cents for weeks, NVD jumped up nearly 40% on Friday on volume that is right in line with the stock's three month average. The spike could have just been a result of the general market rally or possibly the result of news that may be released this week.

With a plethora of patents expiring in the next few years, Big pharma has been on the hunt for new drug pipelines via buyouts, takeovers and mergers, as evidenced by Insmed's $130 Million Payday, and Novadel is as good a buyout or partnership candidate as any.

Novadel, with it's two approved drugs, may have a bright future ahead but that is not to say that an investment in NVD is without risk. Small biotechs, even with approved drugs, are always risky, but this one is a risk worth taking, in my opinion, while it is trading for a couple of dimes. The upside could be a couple of hundred percent while the downside is four pieces of Bazooka Joe bubble gum.

The 40% spike on Friday makes NVD a stock worth watching this week.

VFC's Stock Picks: NVD

Paradysz Matera

BBI, Blockbuster Inc:

Three Stocks That Will Recover and Three That Won't

The Blockbuster stock also enjoyed a 40% gain on Friday, and while the stock has been a great play for day traders of late, this is a gain that is unwarranted, in my opinon.

I've outlined my case against Blockbuster surviving and barring an exponential shift in the company's business plan, I don't see anything drastically altering the future shape of the company.

Blockbuster is years behind the competition and even while their fiscal 2008 results were not that bad, they lost money in their primary business operation- renting DVDs and Video Games.

The competition from streaming media, discount renters and Netflix is growing every day and Blockbuster's days are numbered.

Of course, this is all just VFC's opinon.

For the day traders out there that enjoy a wild ride, BBI has been hugely volatile lately and will provide dips and spikes, but the long term investor should stay far away. There are plenty of other undervalued bargains out there to chase that are a lot less risky.

Don't be fooled by Blockbuster's 40% gain on Friday.

An Additional $5 Off $35 or more at fye.com coupon code=5OFF35MAR23

Netflix, Inc.

Thursday, March 12, 2009

Update: Sirius XM is Going iPhone and Celsius Sells Out in Phillie

SIRI, Sirius XM:

Sirius XM (SIRI) just released some much anticipated news regarding it's iPhone and iPod applications, and, in the midst of a market-wide rally, the news release was good enough for a 20% jump in stock price.

Fresh off a Liberty Media bailout from the verge of bankruptcy, Sirius XM has just given listeners a new means of enjoying the wide variety of content which is only offered by Sirius XM without having to buy a SatRad receiver.

As the market for new cars dwindles, and thereby hurting Sirius XM's subscription growth, the iPhone application will give the company exposure, and likely a new revenue stream, to offset the loss of vehicle subscribers. Combining Sirius XM with the iPhone is just as good as any TV ad campaign, in my opinion.

The thought of being able to listen to every MLB and NFL game on the iPhone makes me want to go out and buy one right now.

As for the stock, I thought it was a steal at under ten cents, and those that bought on the news of a possible bankruptcy are sitting pretty right now.

VFC is long and strong on SIRI, but I may trade in and out on these spikes and dips.

Sirius Satellite Radio Inc.

CSUH.OB, Celsius Holdings:

As a followup to my last Celsius post, word is that Celsius may have sold out many locations in Philadelphia as a result of the local CBS affiliate's Health report that aired three days ago.

Click HERE for my last post and a link to the CBS report.

I've been in contact with a Celsius fan located in Philadelphia who has informed me that after the show aired, she went and tried to purchase some of the product and was only able to buy the last four-pack of Green Tea/Mango at a local GNC. According to the contact in Phillie, who also visited a sold-out Vitamin Shoppe, the GNC staff stated that their entire district had sold out.

I did not personally verify this information, but this is an example of what some exposure could do for product sales, which in turn could, eventually, influence the price of the stock.

select 3

Stock Round-Up: GE and CVM

GE, General Electric:

Last week at VFC's Stock House, GE was labelled as a stock that would certainly recover with a market rebound.

It wasn't much of a risky call because it's not to hard to find an undervalued rebound stock in the bear market, but GE has been beat down more than most after some bad press and poor numbers from their finance division.

Additionally, anticipation of a credit rating cut had GE trading near six dollars, even while the company insisted that they did not expect a drastic cut from the AAA mark.

Today, the company received the expected rating cut, but only to AA+; down only one notch and far from the drastic cut that many 'experts' were predicting. More significantly, the S&P gave General Electric a 'stable outlook', which is one reason for today's wide-market rally and assuredly the primary reason for the 14% jump in the GE stock price.

There may be some profit taking after this rally, and there is no guarantee that this is the market rebound that everyone is waiting for (in VFC's opinion, this is not the big rebound, but widespread short covering), but GE is one stock that is still worth buying on the dips, in my opinion, and one of my long term favorites- while it is trading for under ten bucks.

234x60_Money Aisle

CVM, Cel-Sci Corp:

CVM enjoyed a near 30% gain today and is another stock that has been hammered in recent months. This stock is a high-risk, high-reward play because the company currently has a Phase III clinical trial for it's head and neck cancer compound, Multikine, on hold while the overall market and credit crunch straighten out.

In the meantime, the company just released two fairly significant pieces of news in the last week.

The first Press Release reported another Multikine licensing agreement; this one with Byron Biopharma ("Byron") who gains the rights to market and distribute Multikine in the Republic of South Africa. Along with this agreement, Byron will purchase $750,000 worth of stock from CEL-SCI and will make a payment of $125,000 in 12 months. Not a bad deal for a small biotech during a world-wide recession. Cel-Sci will manufacture the drug, Byron will sell it and the proceeds will be split 50/50. Cel Sci also has existing licensing agreements with Teva Pharmaceuticals and Orient Europharma. All of this, of course, means little if Multikine fails to gain approval.

While licensing agreements are definitely not a negative indication, they cannot be viewed as positive either- it's safest to take them with a grain of salt because without an approved drug, a licensing agreement means nil. Cell Genesys (CEGE), for instance, had a significant agreement in place for it's cancer vaccine GVAX that meant nothing once the clinical trials indicated that GVAX didn't work.

However, the fact that Cel Sci was able to find three other companies willing to license Multikine based on Phase II results should be viewed as somewhat encouraging.

Previous Post Regarding CVM

In another piece of news, the company announced that < taken directly from the Press Release > it is planning to launch a new manufacturing process that could allow drugs developed using stem cells and other biological products to maintain their potency and thereby potentially also their shelf life.

With the President just recently issuing an Executive Order that will allow federal funding to be used for Stem Cell Research, this new shelf-life-extending process, which Cel Sci needed for it's own production of Multikine, could come in as a nice little money-maker.

CVM is a nice long term pick due to the potential of Multikine (labeled as a potential blockbuster by MedAdNews), especially when the share price is in the twenty cent range, where it has been for quite some time.

I plan on sitting on this one for a while, but if Multikine makes it, look out for the blast-off.

More importantly, if Multikine makes it, that will mean that there is new hope and a novel medical treatment available to victims of maybe the most fatal form of cancer.


Great News For These Three Stocks
Dendreon's Early Results
VFC's Bear Market Stock Picks Part I
VFC's Bear Market Picks Part II
VFC's Bear Market Picks Part III
VFC's Bear Market Non Picks Part
VFC's Stock Updates
VFC's Bear Market Picks Part IV; CRYP, CSUH.OB
VFC's Biotech Picks
VFC's Quarterly Updates
INSM Update, IPLEX Back In Action

Jim Cramer is really 'Mad'

Cramer, the star of CNBC’s well-known stock picking show ‘Mad Money’, has recently come under fire from Jon Stewart of the Comedy Channel for encouraging investors to buy stock in Bear Sterns before that company’s stock price collapsed. In a small segment during his program, Stewart aired two clips of Cramer advising, and at one point pleading, for investors to buy stock in the company and made light of the fact that Cramer, an ‘expert’ stock picker, was wrong.

During an appearance on NBC’s Today Show where Cramer had a chance to defend himself, he looked to be taking the whole thing a little too personally. In his defense, he pointed out the fact that he had advised his viewers to sell all of their holdings “35% ago”, yet Stewart, Cramer said, failed to mention that fact. Cramer looked visibly shaken and stirred as the Stewart clip played; he looked like someone who was taking business a little too personal.

Cramer’s performance goes right in line with VFC’s previous postings regarding the big boys and the fact that they are more concerned about their egos than anything else.

As the Warren Buffet legacy deteriorates right in front of our very eyes on a daily basis, Jim Cramer may also be approaching the road to irrelevancy. He nearly broke down into tears in front of a national television audience on the Today show while defending his Bear Sterns pick where he, time and again, made it a point to remind viewers that Stewart is only a comedian; a great enlightenment for those who couldn’t make the connection that Stewart’s program airs on the COMEDY channel.

However, even a comedian can figure out when someone got it wrong. In Cramer’s case, rather than admit to a mistake, he blames the market and the fact that the SEC is investigating the Bear Stearns CEO to bail out his ego. In other words, a la Barney Frank and his call on Fannie and Freddie, Cramer is additional proof that the big boys have a hard time saying, “I got that one wrong.”

In the past, Cramer has admitted to making some bad picks, but he subsequently admitted his mistake and apologized for them on his show. Mindspeed Technologies (MSPD) comes to mind; a few years ago, for the duration of a ‘Mad Money’ episode, Cramer wore a yellow sticky that read ‘MSPD’ on his forehead to remind viewers that even he can get the picks wrong now and again. He’s also flip-flopped a number of times while attempting to predict the direction of the SIRI stock, which now hovers in the teens (cents).

So Cramer’s vehement defense of his Bear Stearns pick actually comes as quite a surprise. He’s never before let a bad call rattle him as Jon Stewart did. It’s uncanny that someone’s who screams and jumps around like a raging lunatic on his television show can be so soft-skinned when someone throws a little jab at him.

If he’s gotten picks wrong before and then admitted he was wrong, what is so different now?

VFC has two theories:

First, as Cramerica (as he likes to call his fan base) gets bigger and bigger (along with his self-proclaimed relevancy, he has a harder time admitting his mistakes and an even harder time watching someone else point them out. I’ll call this the ‘Warren Buffet’ syndrome- someone who is on top does not like to look bad, and both Cramer and Bufett them look pretty bad right now. I do not know if Cramer still acknowledges his mis-calls because I have not watched his program since he told America to stay out of the market for five years. It was a safe call on his part because he can now claim that he saved Americans “35%” whenever he makes a wrong call, but it was an irresponsible call because now is the time for average Americans, that can afford to, to position themselves for building wealth not run scared. This call will look worse and worse as the market goes higher because the market will surpass the level where Cramer said ‘Sell’ within five years, and those lost gains where the small investor would have made their money back will never happen because Cramer had his viewers ‘realize’ their losses. Cramer was more looking out for himself with that call than for the average investor.

In short, this theory says that Cramer simply does not like looking bad and Stewart rattled his ego a little bit.

The second theory is purely speculation, but maybe Cramer has an agenda. After all, he still has contacts in the hedge fund world and on Wall Street, and guys that have made as much money as Cramer has cannot stop themselves from wanting to make more. The paragraphs of disclaimer that accompany an episode of ‘Mad Money’ advise viewers not to trade simply on ‘Cramer’s take’, but there is little to stop Cramer from using his platform to promote his own, or someone else’s, investing agenda.

This goes for the entire CNBC network; it’s usually not too hard to figure out which stocks the network wants to pump and which ones they want to dump.

If this second theory is actually correct, then it would explain Cramer’s uncomfortable behavior when Stewart essentially hit the nail on the head.

In actuality, I believe that theory number one is correct- Cramer’s ego has gotten so large that he cannot bear to have someone make him look like an idiot while he’s doing what he does best.

Cramer has his faults and his credibility is sagging, but his books are still a great place to acquire a basic insight into stock and options trading for the start-up investor. Real Money, Mad Money and Stay Mad for Life are great reads and should not be discounted.

Cramer will appear on Jon Stewart's show tonight.


Tuesday, March 10, 2009

MLB Playing Hardball With Sirius

While the NFL, NBA, NASCAR and the NHL have all agreed to allow their games to air on both Sirius and XM after the two companies merged, Major League Baseball has thrown a curve to the company and wants to renegotiate the contract before allowing the nearly 20 million SatRad fans to have access to their games.

With MLB having the reputation of being the league that rips off the fans the most, it is not surprising that they are asking for more than the $650 million already agreed to- especially in a time of economic crisis.

Sirius XM is a company that was teetering on the brink of collapse until Liberty Media came in with a bailout and you can't help but think that MLB is picking on the little guy- again.

Sirius satRad listeners have been waiting for the oppourtunity to tune into every pitch of every MLB game this season, just as XM fans can catch every down of every NFL game on their receivers, but MLB does not want to let that happen.

I suggest Sirius XM listeners contact the MLB offices via email or phone and express disgust towards this decision.

No one should be surprised, however, from this move by a league that throws money around like the DOW is at 14,000.

Sirius Satellite Radio Inc.

Celsius (CSUH.OB) Gains Some Publicity

The calorie burning energy drink Celsius gained some publicity today when a CBS affiliate in Philadelphia aired a segment which highlighted the benefits of drinking Celsius as an integral part of any weight-loss program.

The report tracked a woman who lost 170 pounds with a vigorous exercise routine combined with the effects of drinking Celsius before her workouts. Also highlighted were the four clinical trials that verify Celsius's calorie burning claims.

As the distribution of Celsius ramps up, publicity like this local news report, along with the Katie Holmes spotting, can't help but boost the growing popularity of the drink- which in turn should make investors of CSUH.OB very happy.

That is not to say there is no risk involved with CSUH.OB- all start up companies laden with debt are risky, but the growing popularity of Celsius resulting from a consumer awareness campaign that seemed to coincide with the arrival of Carl DeSantis to the company gives investors confidence moving forward.

The sparkling Celsius flavors should gain a foothold in the market as a healthy alternative to the sugar-laden energy drinks that are out there now and the Green Tea brands offer an alternative to the five carbonated flavors.

As the product grows in distribution and popularity, more weight-loss stories such as the one that aired on CBS should emerge.

The downside is minimal with this stock, trading at four cents, but the upside could be huge.

Link to CBS Story
Link to CBS Health Segment Video

Celsius Catches on With Katie Holmes
VFC's 2009 Stock Picks
Comments from Celsius CEO Steve Haley
Comments from Celsius CEO Steve Haley, Part I
ShareBuilder - Welcome page

Insmed's IPLEX Given the Experimental Green Light by the FDA to Treat ALS

Barely a month after receiving a hefty $130 million payday, Insmed, Inc released some additional good news regarding it's lead drug IPLEX.

Today, the company announced that the FDA will allow experimental use of IPLEX for patients with ALS, commonly known as Lou Gherig's disease. The FDA's decision to allow patients access to IPLEX opens the door for an alternative to current treatments which have not been proven effective. The use of IPLEX for the treatment of ALS has been proven safe and tolerable in an ongoing expanded access program in Italy. The experimental approval in the United States also comes as a significant victory for a lobby of ALS patients and family members who have been pushing for access to IPLEX for some time.

IPLEX is already approved by the FDA to treat short stature in children but cannot be used in that indication due to a patent infringement case in which Insmed lost.

While the FDA decision gives new hope to ALS patients, the decision also benefits investors who own the INSM stock.

Today's news has pushed the price of INSM to over $1.00, making it a double from only a few months ago. This price level brings the market cap of the company to roughly equal to the cash value. Since Insmed sold their Follow-on-biologics pipeline, any rise in price from here will be due to the potential of IPLEX- and potential there is.

With IPLEX already in use for the treatment of ALS in Italy and the FDA decision to allow it's experimental use in the States, the company and the stock are both positioned for significant growth. Combine that with the fact that Phase II data from ongoing MMD trial is due at any time and INSM could turn into a real winner.

Big Pharma is out looking to boost their pipelines, as demonstrated by the sale of Insmed's FOB candidates, and Insmed all of a sudden looks like a great target for a big partnership or even a buyout.

It's been tough to find the 'doubles' in this market, but INSM has rewarded investors handsomely, and the potential for even bigger gains still exists.

Previous Insmed Posts:
VFC's Follow-on Biologics Pick, INSM
INSM: Signs of Life
Insmed Update
VFC's Bear Market Picks, AGEN, MVL, INSM, CSUH.OB
IPLEX Update

ShareBuilder - Welcome page

The Latest on Warren Buffet

For all of his money, power and influence, Warren Buffet has reached the point in his life where his interest in hearing himself talk overshadows his investing prowess.

As I've recently pointed out, the big boys like Buffet don’t like to be wrong and when they are wrong, they go into damage control mode to protect their own image; usually to the detriment of the little guy that is looking for leadership.

In the case of Buffet, months ago he called a ‘Buy’ market when and then gobbled up millions of shares of a plunging General Electric (GE) stock. More importantly, President Obama hailed Warren Buffet as one of his economic advisors in an attempt to win support for his stimulus package and economic policy. With Buffet's name forever attached to Barack Obama's policies, if Obama’s policies fail, then it is also a failure for Buffet.

The market undoubtedly views policies as failures because every time the President speaks on economic policy, the market drops about a hundred points; that’s a tough pill for the Great Buffet to swallow.

Now the spin control is in full effect and Buffet is attempting to explain his misjudgments by resorting to the ‘fear tactic’, or his version of that tactic which is the ‘worst case scenario’ tactic.

When Buffet talks about how the economy has ‘fallen off a cliff’, he’s hoping that we understand that not even he could have foreseen this coming, thus softening the blow to his image and his ego.

In a recent interview with CNN, he also stated that he has never seen Americans so fearful. Really? No kidding. When the likes of the President, Jim Cramer and Warren Buffet are telling Americans on a daily basis how terrible things are and that there is little promise of a turnaround, then how would they be expected to react? The fear talk emanating from America’s finest economic minds has most likely caused more people to sell their holdings at a huge loss than the recession itself. His comment that the economy will be fine in five years does little to quell the fears of today, and makes you wonder why he even needed to scare people todayselling if he believes a turnaround is inevitable. Again, he just likes to hear himself talk.

Also, Buffet took a page from John Madden’s playbook and, as a master of the obvious, he told CNN viewers that people weren’t spending money anymore, especially not on luxury items. Glad that’s cleared up, I had my doubts.

The CNN interview offered nothing, especially not anything new. Buffet is still to be revered for his investing prowess, but the CNN interview displayed a great man in decline.

Warren Buffet is an American Icon and maybe the shrewdest investor that has ever lived, but it’s time for the big guy to hang it up and enjoy all that money on a beach somewhere (where there’ll assuredly be some Congressmen relaxing themselves on the taxpayer’s dime).

Right now Buffet is the 43-year-old southpaw reliever with the 4.86 ERA that just won’t hang up the cletes.

There’s something to be said for going out on top.

But then again, even if Buffet did get out of the game now, is he really out with his name attached to the Obama economic policy?

Make no mistake, Buffet is not on television to give investing advice to the average American or to offer a way out of this mess; he's out there to protect his own image.


ShareBuilder - Welcome page


Follow by Email